These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18201212)

  • 21. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
    Fritsche A; Stefan N; Hardt E; Schützenauer S; Häring H; Stumvoll M
    Eur J Clin Invest; 2000 May; 30(5):411-8. PubMed ID: 10809901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.
    Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ
    Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
    Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.
    Wu L; Olverling A; Fransson L; Ortsäter H; Kappe C; Gao X; Sjöholm A
    Regul Pept; 2012 Aug; 177(1-3):92-6. PubMed ID: 22587909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
    Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
    Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.
    Yan P; Li L; Yang M; Liu D; Liu H; Boden G; Yang G
    Diabetes Res Clin Pract; 2011 Jun; 92(3):368-74. PubMed ID: 21458097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
    Porter DW; Kerr BD; Flatt PR; Holscher C; Gault VA
    Diabetes Obes Metab; 2010 Oct; 12(10):891-9. PubMed ID: 20920042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2010; 65(7-8):464-70. PubMed ID: 20857706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet.
    Winzell MS; Brand CL; Wierup N; Sidelmann UG; Sundler F; Nishimura E; Ahrén B
    Diabetologia; 2007 Jul; 50(7):1453-62. PubMed ID: 17479245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 38. Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
    Shao Y; Yuan G; Feng Y; Zhang J; Guo X
    Peptides; 2014 Feb; 52():134-42. PubMed ID: 24406898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
    Polderman JA; Houweling PL; Hollmann MW; DeVries JH; Preckel B; Hermanides J
    BMC Anesthesiol; 2014; 14():91. PubMed ID: 25419179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.
    Horowitz M; Vilsbøll T; Zdravkovic M; Hammer M; Madsbad S
    Diabetes Obes Metab; 2008 Jul; 10(7):593-6. PubMed ID: 18435773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.